Pharmaceutical Administration and Regulations in Japan - Nihs
Pharmaceutical Administration and Regulations in Japan - Nihs
Pharmaceutical Administration and Regulations in Japan - Nihs
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
eevaluation of gastro<strong>in</strong>test<strong>in</strong>al drugs, dermatologic<br />
drugs, hormone preparations, <strong>and</strong> metabolic<br />
disease drugs (e.g., anti-diabetic, osteoporosis,<br />
gout, <strong>and</strong> congenital metabolic disorder drugs)<br />
4.2 Office of New Drug II<br />
This office confirms cl<strong>in</strong>ical trial notifications <strong>and</strong><br />
adverse drug reactions <strong>and</strong> conducts reviews<br />
required for approval, reexam<strong>in</strong>ations <strong>and</strong><br />
reevaluation of new cardiovascular drugs, drugs to<br />
treat Park<strong>in</strong>son’s disease, drugs to improve<br />
cerebral circulation <strong>and</strong> metabolism, drugs to treat<br />
Alzheimer’s disease, urogenital <strong>and</strong> anal drugs,<br />
comb<strong>in</strong>ation drugs, radiopharmaceuticals, <strong>and</strong><br />
contrast media.<br />
4.3 Office of New Drug III<br />
This office confirms cl<strong>in</strong>ical trial notifications <strong>and</strong><br />
adverse drug reactions <strong>and</strong> conducts reviews<br />
required for approval, reexam<strong>in</strong>ations, <strong>and</strong><br />
reevaluation of new central nervous system drugs,<br />
peripheral nervous system drugs, anesthetic<br />
agents, sensory organ drugs (other than drugs for<br />
<strong>in</strong>flammatory diseases), <strong>and</strong> narcotics.<br />
4.4 Office of New Drug IV<br />
This office confirms cl<strong>in</strong>ical trial notifications <strong>and</strong><br />
adverse drug reactions <strong>and</strong> conducts reviews<br />
required for approval, reexam<strong>in</strong>ations, <strong>and</strong><br />
reevaluation of antibacterial drugs, antiparasitic<br />
agents, antiviral agents (except for anti-HIV/AIDS<br />
agents), new respiratory tract drugs, anti-allergy<br />
drugs sensory organ drugs (limited to drugs for<br />
<strong>Pharmaceutical</strong> <strong>Regulations</strong> <strong>in</strong> <strong>Japan</strong>:<br />
<strong>in</strong>flammatory diseases), <strong>and</strong> anti-HIV/AIDS agents.<br />
4.5 Office of New Drug V<br />
This office confirms cl<strong>in</strong>ical trial notifications <strong>and</strong><br />
adverse drug reactions <strong>and</strong> conducts reviews<br />
required for approval, reexam<strong>in</strong>ations, <strong>and</strong><br />
reevaluations of ant<strong>in</strong>eoplastic drugs.<br />
4.6 Office of Biologics I<br />
In the Office of Biologics, the PMDA confirms<br />
cl<strong>in</strong>ical trial notifications <strong>and</strong> adverse drug reactions<br />
<strong>and</strong> conducts reviews required for approval,<br />
reexam<strong>in</strong>ations, <strong>and</strong> reevaluation of globul<strong>in</strong>s,<br />
blood coagulation factor products, etc.<br />
This office also undertakes prelim<strong>in</strong>ary reviews<br />
for applications for verification of drugs for gene<br />
therapy <strong>and</strong> medical devices us<strong>in</strong>g cells <strong>and</strong><br />
tissues, prelim<strong>in</strong>ary reviews for applications for<br />
approval or verification based on the Cartagena<br />
Protocol, <strong>and</strong> quality review of antibody<br />
preparations.<br />
4.7 Office of Biologics II<br />
This office confirms cl<strong>in</strong>ical trial notifications <strong>and</strong><br />
adverse drug reactions of vacc<strong>in</strong>es, antidotes, <strong>and</strong><br />
drugs for cell therapy <strong>and</strong> performs the reviews<br />
required for approval, reexam<strong>in</strong>ation, or<br />
reevaluation.<br />
The office also performs prelim<strong>in</strong>ary reviews for<br />
approval applications of drugs <strong>and</strong> medical devices<br />
us<strong>in</strong>g cells <strong>and</strong> tissues.<br />
2011-3 - 8 -